Montelukast for bronchiolitis Obliterans syndrome after lung transplantation

Chest

Volumn 141, Issue 1, 2012, Pages 275-276

  Simons, Sami O ^a   Reijers, Monique H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR; MONTELUKAST;

BRONCHIOLITIS OBLITERANS; CD8+ T LYMPHOCYTE; DRUG EFFECT; EFFECTOR CELL; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; HUMAN; LETTER; LUNG TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECEPTOR UPREGULATION; T LYMPHOCYTE;

EID: 84855457844     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-1979     Document Type: Letter

References (4)

1. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the fi nal frontier for lung transplantation. Chest. 2011;140(2):502-508.
2. Medoff BD, Seung E, Wain JC, et al. BLT1-mediated T cell trafficking is critical for rejection and obliterative bronchiolitis after lung transplantation. J Exp Med. 2005;202(1):97-110. (Pubitemid 41002913)
3. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999;340(3):197-206. (Pubitemid 29063217)
4. Verleden GM, Verleden SE, Vos R, et al. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study. Transpl Int. 2011;24(7):651-656.